Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
pharmaand GmbH clinical trials
Also known as pharma&.
The registry lists 22 studies whose lead sponsor is pharmaand GmbH. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Jul 25, 2025.
Registry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to pharmaand GmbH.
- pharmaand GmbH22 studiesSame company
Something wrong?
Studies
Recruiting first, then most recently updated. Showing 22 of 22.
- A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene DeficiencyCompletedNCT02975934Phase 3
- A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based ChemotherapyActive, not recruitingNCT03522246Phase 3
- Panobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple MyelomaCompletedNCT02654990Phase 2
- CATCH-R: A Rollover Study to Provide Continued Access to RucaparibCompletedNCT04676334Phase 3
- A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR)TerminatedNCT03992131Phase 1/2
- A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR GenesTerminatedNCT04171700Phase 2
- Study of Oral Rucaparib With Other Anticancer Agents in Metastatic Castration Resistant Prostate Cancer Patients (RAMP)CompletedNCT04179396Phase 1
- A Disease Registry Encompassing the Care Of Patients With Multiple Myeloma on PanobinostatCompletedNCT04150289
- A Study of Rucaparib in Patients With Pancreatic Cancer and a Known Deleterious BRCA MutationCompletedNCT02042378Phase 2
- A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)CompletedNCT01891344Phase 2
- A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES)TerminatedNCT03824704Phase 2
- Rucaparib in Patients With Locally Advanced or Metastatic Urothelial CarcinomaTerminatedNCT03397394Phase 2
- ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer PatientsCompletedNCT02855944Phase 3
- A Study of Rucaparib in Japanese Patients With a Previously-treated Solid TumorCompletedNCT03499444Phase 1
- A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene DeficiencyCompletedNCT02952534Phase 2
- Pharmacokinetic Drug-Drug Interaction Study of RucaparibCompletedNCT02740712Phase 1
- Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid Ovarian Cancer (ARIEL3)CompletedNCT01968213Phase 3
- Absorption, Metabolism, and Excretion Following a Single Oral Dose of [14C]-RucaparibCompletedNCT02986100Phase 1
- Rucaparib Hepatic Impairment Study in Patients With a Solid TumorCompletedNCT03521037Phase 1
- A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II)CompletedNCT01482715Phase 1/2
- Drug-Drug Interaction Study of Rucaparib, Rosuvastatin and Oral ContraceptivesCompletedNCT03954366Phase 1
- A Study Of Poly (ADP-Ribose) Polymerase Inhibitor PF-01367338 In Combination With Several Chemotherapeutic RegimensCompletedNCT01009190Phase 1